Risk Factors for Hepatocellular Carcinoma in Hepatitis C Patients
Author Information
Author(s): Sabina Mahmood, Kazumi Kawanaka, Miwa Niiyama, Gouichi Yamada
Primary Institution: Kawasaki Medical School
Hypothesis
What factors contribute to the development of hepatocellular carcinoma in hepatitis C patients with stage 3 fibrosis after interferon therapy?
Conclusion
Maintaining low alanine aminotransferase levels for three years may help prevent hepatocellular carcinoma in hepatitis C patients.
Supporting Evidence
- 26 out of 55 patients developed hepatocellular carcinoma over 12 years.
- Patients with continuously low ALT levels did not develop HCC.
- Initial interferon response was significantly related to HCC development.
Takeaway
If you have hepatitis C and keep your liver enzyme levels low for a long time, you might not get liver cancer.
Methodology
55 chronic hepatitis C patients were followed for 12 years to assess risk factors for hepatocellular carcinoma development.
Limitations
The study had a small sample size and fewer patients were re-treated with interferon.
Participant Demographics
24 males and 31 females, average age 60.8 years.
Statistical Information
P-Value
0.05
Confidence Interval
95% CI: 0.88–5.09
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website